X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Wockhardt with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT vs MYLAN (US) - Comparison Results

WOCKHARDT    Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 WOCKHARDT   MYLAN
EQUITY SHARE DATA
    WOCKHARDT
Mar-18
MYLAN
Dec-14
WOCKHARDT/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1,0124,142-   
Low Rs5322,919-   
Sales per share (Unadj.) Rs355.91,417.8-  
Earnings per share (Unadj.) Rs-60.3170.8-  
Cash flow per share (Unadj.) Rs-46.8274.9-  
Dividends per share (Unadj.) Rs0.010-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs257.8704.8-  
Shares outstanding (eoy) m110.63378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x2.22.5 87.1%   
Avg P/E ratio x-12.820.7 -61.9%  
P/CF ratio (eoy) x-16.512.8 -128.5%  
Price / Book Value ratio x3.05.0 59.8%  
Dividend payout %00-   
Avg Mkt Cap Rs m85,3791,335,681 6.4%   
No. of employees `0006.325.0 25.0%   
Total wages/salary Rs m9,3710-   
Avg. sales/employee Rs Th6,295.021,458.5 29.3%   
Avg. wages/employee Rs Th1,498.30-   
Avg. net profit/employee Rs Th-1,066.32,585.0 -41.2%   
INCOME DATA
Net Sales Rs m39,369536,463 7.3%  
Other income Rs m1,202-3,127 -38.4%   
Total revenues Rs m40,571533,336 7.6%   
Gross profit Rs m18133,421 0.0%  
Depreciation Rs m1,49539,401 3.8%   
Interest Rs m2,55523,140 11.0%   
Profit before tax Rs m-2,83067,753 -4.2%   
Minority Interest Rs m0-278 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,5820-   
Tax Rs m2572,849 9.0%   
Profit after tax Rs m-6,66964,626 -10.3%  
Gross profit margin %024.9 0.2%  
Effective tax rate %-9.14.2 -216.0%   
Net profit margin %-16.912.0 -140.6%  
BALANCE SHEET DATA
Current assets Rs m33,796471,622 7.2%   
Current liabilities Rs m26,917368,714 7.3%   
Net working cap to sales %17.519.2 91.1%  
Current ratio x1.31.3 98.2%  
Inventory Days Days7978 101.6%  
Debtors Days Days89107 83.2%  
Net fixed assets Rs m39,664124,109 32.0%   
Share capital Rs m55318,971 2.9%   
"Free" reserves Rs m27,9680-   
Net worth Rs m28,522266,675 10.7%   
Long term debt Rs m21,731398,386 5.5%   
Total assets Rs m81,6201,074,142 7.6%  
Interest coverage x-0.13.9 -2.7%   
Debt to equity ratio x0.81.5 51.0%  
Sales to assets ratio x0.50.5 96.6%   
Return on assets %-5.08.2 -61.7%  
Return on equity %-23.424.2 -96.5%  
Return on capital %-7.713.6 -56.3%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m8,0190-   
CASH FLOW
From Operations Rs m68470,518 1.0%  
From Investments Rs m6,302-55,613 -11.3%  
From Financial Activity Rs m-7,695-18,582 41.4%  
Net Cashflow Rs m-664-3,676 18.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 69.49 Rs / USD

Compare WOCKHARDT With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare WOCKHARDT With: IPCA LABS  ALEMBIC PHARMA  UNICHEM LAB  CIPLA  GLENMARK PHARMA  



Today's Market

Modi's Victory Creates Sensex History; Ache Din Ahead?(Podcast)

Throughout the week, one slogan that took over the market and country as a whole was, Ab ki baar phir Modi Sarkar.

Related Views On News

WOCKHARDT Announces Quarterly Results (4QFY19); Net Profit Up 90.8% (Quarterly Result Update)

May 7, 2019 | Updated on May 7, 2019

For the quarter ended March 2019, WOCKHARDT has posted a net profit of Rs 139 m (up 90.8% YoY). Sales on the other hand came in at Rs 10 bn (down 3.8% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (3QFY19); Net Profit Down 80.6% (Quarterly Result Update)

Jan 29, 2019 | Updated on Jan 29, 2019

For the quarter ended December 2018, WOCKHARDT LTD. has posted a net profit of Rs 769 m (down 80.6% YoY). Sales on the other hand came in at Rs 10 bn (up 4.0% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

3 Stocks to Bet on to Become a 'Dividend Millionaire'(Profit Hunter)

May 14, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

Indian Steel: The Perfect Multibagger Opportunity(Profit Hunter)

May 17, 2019

A structurally strong Indian Steel Industry will help India achieve 8%+ GDP growth in the coming years.

What Makes TVS Srichakra and CCL Products a Cut Above the Rest?(The 5 Minute Wrapup)

May 17, 2019

Despite the commodity nature of their businesses, these two stocks have rewarded shareholders well.

The Bitter Pill that Will Lay the Foundation for Sensex 100,000(The 5 Minute Wrapup)

May 14, 2019

These companies will help the Sensex more than double from current levels.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT SHARE PRICE


May 24, 2019 (Close)

TRACK WOCKHARDT

  • Track your investment in WOCKHARDT with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE WOCKHARDT WITH

MARKET STATS